Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 10/20 | 0.63 |
| ▸ | TACR1 | P25103 | 5/20 | 0.50 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2782707 | 0.85 | SCN4A (0.68) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL22051985 | 0.83 | SCN4A (0.65) | SCN4ATACR1 | |
| SCHEMBL18217370 | 0.81 | SCN4A (0.63) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL28547611 | 0.79 | SCN4A (0.61) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL21995447 | 0.79 | SCN4A (0.61) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL57799 | 0.79 | SCN4A (0.61) | SCN4ATACR1 | |
| SCHEMBL791984 | 0.79 | SCN4A (0.61) | SCN4ATACR1 | |
| SCHEMBL1419721 | 0.79 | SCN4A (0.61) | SCN4ATACR1 | |
| SCHEMBL21995096 | 0.77 | SCN4A (0.59) | SCN4ATACR1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL21995098 | 0.77 | SCN4A (0.59) | SCN4ATACR1CACNA1FCACNA1DCACNA1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835392-B2 | Mimetic peptides and the use thereof in the form of 20S, 26S and immunoproteasome inhibitors | Technische Universität (DE) | 2014-09-16 | — | — | US | disclosed |
| US-20140228543-A1 | MODIFIED AND DERIVATIZED ß-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS | MIDCAP FINANCIAL TRUST, AS AGENT | 2014-08-14 | — | — | US | disclosed |
| WO-2012154680-A2 | MODIFIED AND DERIVATIZED β-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS | BIOTHERA, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20090012007-A1 | Mimetic Peptides and the Use Thereof in the Form of 20S, 26S and Immunoproteasome Inhitibors | CHARITE UNIVERSITATSMEDIZIN BERLIN (DE) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228543-A1 | MODIFIED AND DERIVATIZED ß-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS | MANBA, ALG1, MAN2A1 | SCN4A 1871/4885TACR1 4851/4885CACNA1F 3913/4885 |
| US-20090012007-A1 | Mimetic Peptides and the Use Thereof in the Form of 20S, 26S and Immunoproteasome Inhitibors | IAPP, PSMB3, PSMB5 | SCN4A 2193/4885TACR1 4120/4885CACNA1F 4645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.